This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Stribild (HIV) - Forecast And Market Analysis To 2022

NEW YORK, April 11, 2013 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

Stribild (HIV) - Forecast and Market Analysis to 2022

Stribild (HIV) - Forecast and Market Analysis to 2022

SummaryGlobalData has released its new PharmaPoint Drug Evaluation report, "Stribild (HIV) - Forecast and Market Analysis to 2022". Human Immunodeficiency Virus (HIV), the causative agent of AIDS, has claimed millions of lives since its emergence. However, the advent of antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a deadly disease to a manageable chronic condition for most infected individuals. Antiretroviral treatment not only reduces the viral load and reconstitutes immune function, but also decreases infection incidence rates by limiting viral transmission. The treatment algorithm in HIV has characteristically involved multiple drug regimens designed to tackle the virus on different levels. In the recent past, simplified dosing regimens through the emergence of single tablet regimens (STRs) or fixed dose combination (FDC) therapies have become increasingly popular amongst physicians and patients alike by increasing clinical efficacy thresholds and enabling patient compliance.Gilead's Stribild is a complete, fixed-dose regimen for antiretroviral-treatment-naïve adults with HIV. Stribild contains two NRTIs (emtricitabine/FTC and tenofovir disoproxil fumarate/TDF), a novel INI (elvitegravir/ELV) and a novel PK enhancer (cobicistat/COBI). Stribild's mechanism of action includes the following (Stribild prescribing information, 2012).FTC, a synthetic nucleoside analog of cytidine, inhibits the activity of HIV reverse transcriptase (RT) by competing with a natural substrate deoxycytidine 5'-triphosphate and by being incorporated into nascent viral DNA resulting in the termination of replication.TDF, an acyclic nucleoside phosphonate diester analog of adenosine monophosphate, is converted into its active form (i.e., tenofovir diphosphate) by normal metabolic processes. Tenofovir diphosphate inhibits the activity of the HIV RT by competing with deoxyadenosine 5'-triphosphate (a natural substrate), and terminating viral replication if the drug is incorporated into the viral DNA.ELV inhibits the HIV integrase. This blocks HIV from integrating its DNA into host genomic DNA, which prevents HIV from replicating and propagating.COBI enhances ELV bioavailability by selectively inhibiting cytochrome P450 enzymes of the CYP3A superfamily, which would otherwise decrease the bioavailability and half-life of ELV via metabolism. Cobicistat has no direct anti-HIV activity.

Scope- Overview of HIV, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.- Detailed information on Stribild including product description, safety and efficacy profiles as well as a SWOT analysis.- Sales forecast for Stribild for the top nine countries from 2012 to 2022.- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China

Reasons to buy- Understand and capitalize by identifying products that are most likely to ensure a robust return- Stay ahead of the competition by understanding the changing competitive landscape for HIV- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential- Make more informed business decisions from insightful and in-depth analysis of Stribild performance- Obtain sales forecast for Stribild from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China)

Table of Contents1 Table of Contents 51.1 List of Tables 71.2 List of Figures 72 Introduction 82.1 Catalyst 82.2 Related Reports 83 Disease Overview 103.1 Etiology and Pathophysiology 103.1.1 Etiology 103.1.2 Pathophysiology 133.1.3 Prognosis 133.1.4 Quality of Life 143.2 Symptoms 143.2.1 Primary or Acute Infection 143.2.2 Chronic Infection 143.2.3 Advanced Infection/AIDS 154 Disease Management 164.1 Treatment Overview 165 Competitive Assessment 205.1 Overview 205.2 Strategic Competitor Assessment 206 Stribild (elvitegravir/cobicistat/tenofovir/emtricitabine) 236.1 Efficacy 246.2 Safety 256.3 SWOT Analysis 256.4 Forecast 287 Appendix 297.1 Bibliography 297.2 Abbreviations 317.3 Methodology 337.4 Forecasting Methodology 337.4.1 HIV Prevalence 337.4.2 Percent Drug-Treated Patients 337.4.3 General Pricing Assumptions 347.4.4 Individual Drug Assumptions 357.4.5 Generic Erosion 357.5 Physicians and Specialists Included in this Study 367.5.1 Survery of Prescribing Physicians 377.6 About the Authors 377.6.1 Authors 377.6.2 Global Head of Healthcare 387.7 About GlobalData 397.8 Contact Us 397.9 Disclaimer 39

List of TablesTable 1: Symptoms HIV 15Table 2: Treatment Guidelines for HIV 17Table 3: Most Prescribed Drugs for HIV by Class in the Global Markets, 2012 18Table 4: Leading Treatments for HIV, 2012 22Table 5: Product Profile – Stribild 24Table 6: Stribild SWOT Analysis, 2012 27Table 7: Global Sales Forecasts ($m) for Stribild, 2012-2022 28Table 8: Physicians Surveyed, By Country 37

List of FiguresFigure 1: HIV Lifecycle 11

To order this report: Pathology Industry: Stribild (HIV) - Forecast and Market Analysis to 2022Contact Clare: clare@reportlinker.comUS:(339) 368 6001Intl:+1 339 368 6001


1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.99 -0.02%
FB $99.54 -0.21%
GOOG $678.11 -0.68%
TSLA $148.25 0.18%
YHOO $26.82 -0.85%


Chart of I:DJI
DOW 16,014.38 -12.67 -0.08%
S&P 500 1,852.21 -1.23 -0.07%
NASDAQ 4,268.7630 -14.99 -0.35%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs